Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002 to 2007

Diagnostic Microbiology and Infectious Disease

Volumn 66, Issue 1, 2010, Pages 78-86

  Hoban, Daryl J ^a   Bouchillon, Samuel K ^a   Hawser, Stephen P ^b   Badal, Robert E ^a  

^a Division of Microbiology   (United States)

^b International Health Management Associates Europe Sàrl   (Switzerland)

Author keywords

Multidrug resistance; Surveillance; Susceptibility

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CITROBACTER FREUNDII; CONTROLLED STUDY; DRUG MONITORING; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HUMAN; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; SERRATIA MARCESCENS; SPECIES DIFFERENCE;

EID: 71049140898     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.06.009     Document Type: Article

References (17)

1. Baquero F., Hsueh P.R., Paterson D.L., Rossi F., Bochicchio G.V., Gallagher G., Lantz K., Villasenor J.B., McCarroll K., Abramson M.A., and Chow J.W. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2005 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Surg. Infect. (2008) [Epub ahead of print]
2. Biedenbach D.J., Moet G.J., and Jones R.N. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diag. Microbiol. Infect. Dis. 50 (2004) 59-69
3. Chow J.W., Satishchandran V., Snyder T.A., Harvey C.M., Friedland I.R., and Kinubile M.J. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART). Surg. Infect. 6 (2006) 439-447
4. Felmingham D., and Grüneberg R.N. A multicenter collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: the Alexander Project. J. Antimicrob. Chemother. 38 (1996) 1-57
5. Fraser A., Paul M., Almanasreh N., Tacconelli E., Frank U., Cauda R., Borok S., Cohen M., Andreassen S., Nielsen A.D., Leibovici L., and on be half of the TREAT Study Group. Benefit of appropriate empirical antibiotic treatment: thirty-day mortality and duration of hospital stay. Am. J. Med. 119 (2006) 970-976
6. Lautenbach E., Strom B.L., Nachamkin I., Bilker W.B., Marr, Larosa L.A., and Fishman N.O. Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms. Clin. Infect. Dis. 38 (2004) 655-662
7. Lautenbach E., Metlay J.P., Bilker W.B., Edelstein P.H., and Fishman N.O. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin. Infect. Dis. 41 (2005) 923-929
8. Mazuski J.E., Sawyer R.G., Nathens A.B., DiPiro J.T., Schein M., Kudsk K.A., Yowler C., and for the Therapeutic Agents Committee of the Surgical Infection Society. The surgical infection society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. Surg. Infect. 3 (2002) 161-173
9. Oteo J., Campos J., Baquero F., and and Spanish members of the European Antimicrobial Resistance Surveillance System (EARSS). Antibiotic resistance in 1962 invasive isolates of Escherichia coli in 27 Spanish hospitals participating in the European Antimicrobial Resistance Surveillance System (2001). J. Antimicrob. Chemother. 50 (2002) 945-952
10. Paterson D.L., Rossi F., Baquero F., Hsueh P.R., Woods G.L., Satishchandran V., Snyder T.A., Harvey C.M., Teppler H., DiNubile M.J., and Chow J.W. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J. Antimicrob. Chemother. 55 (2005) 965-973
11. Pfaller M.A., Jones R.N., Doern G.V., Kugler K., and The SENTRY Participants Group. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob. Agents Chemother. 42 (1998) 1762-1770
12. Rossi F., Baquero F., Hsueh P.R., Paterson D.L., Bochicchio G.V., Snyder T.A., Satishchandran V., McCarroll K., DiNubile M.J., and Chow J.W. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J. Antimicrob. Chemother. 58 (2006) 205-210
13. Sahm D.F., Brown N.P., Draghi D.C., Evangelista A.T., Yee Y.C., and Thornsberry C. Tracking resistance among bacterial respiratory tract pathogens: summary of finding of the TRUST surveillance initiative, 2001-2005. Postgrad. Med. 120 (2008) 8-15
14. Sequin P., Laviolle B., Chanavaz C., Donnio P.Y., Gauier-Lerestif A.L., Campion J.P., and Mallédant Y. Factors associated with multidrug-resistant bacteria in secondary peritonitis: impact on antibiotic therapy. Clin. Microbiol. Infect. 12 (2006) 980-985
15. Solomkin J.S., Mazuski J.E., Baron E.J., Sawyer R.G., Nathens A.B., DiPiro J.T., Buchman T., Dellinger E.P., Jernigan J., Gorbach S., Chow A.W., and Bartlett J. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin. Infect. Dis. 37 (2003) 997-1005
16. Stürenburg E., and Mack D. Extended-spectrum β-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control. J. Infect. 47 (2003) 273-295
17. Turner P.J., Greenhalgh J.M., Edwards J.R., and McKellar J. The MYSTIC (meropenem yearly susceptibility test information collection) programme. Int. J. Antimicrob. Agents 13 (1999) 117-125